Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-12-19 00:00:00 ET · period of report 2023-12-15 · accession 0000875320-23-000062 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-19 | 2023-12-15 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $181.83 | +17.1K | 111.8K | +18% | +$3.12M |
| D | 2023-12-19 | 2023-12-15 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale+OE | $407.00 | -17.1K | 108.7K | -14% | -$6.97M |
| DM | 2023-12-19 | 2023-12-15 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $0.00 | -17.1K | 1,565 | -92% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-15 | M | A | 14,077 | $187.53 | 125,846 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-15 | S | D | 17,135 | $407.00 | 108,711 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-15 | M | A | 3,058 | $155.57 | 111,769 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-12-15 | M | D | 3,058 | $0.00 | 0 | D | $155.57 · — to 2028-02-05 | 3,058 Common Stock | (F2) Fully vested. |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-12-15 | M | D | 14,077 | $0.00 | 1,565 | D | $187.53 · — to 2029-02-05 | 14,077 Common Stock | (F2) Fully vested. |